- Home
- RNAC vs CELC Comparison
RNAC vs CELC Comparison
Compare RNAC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- CELC
- Stock Information
- Founded
- RNAC 2007
- CELC 2011
- Country
- RNAC United States
- CELC United States
- Employees
- RNAC N/A
- CELC N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- RNAC Health Care
- CELC Health Care
- Exchange
- RNAC Nasdaq
- CELC Nasdaq
- Market Cap
- RNAC 422.4M
- CELC 489.7M
- IPO Year
- RNAC 2016
- CELC 2017
- Fundamental
- Price
- RNAC $18.27
- CELC $12.81
- Analyst Decision
- RNAC Strong Buy
- CELC Strong Buy
- Analyst Count
- RNAC 7
- CELC 6
- Target Price
- RNAC $41.60
- CELC $29.17
- AVG Volume (30 Days)
- RNAC 113.3K
- CELC 232.9K
- Earning Date
- RNAC 11-07-2024
- CELC 11-14-2024
- Dividend Yield
- RNAC N/A
- CELC N/A
- EPS Growth
- RNAC N/A
- CELC N/A
- EPS
- RNAC N/A
- CELC N/A
- Revenue
- RNAC $47,938,000.00
- CELC N/A
- Revenue This Year
- RNAC $56.06
- CELC N/A
- Revenue Next Year
- RNAC N/A
- CELC N/A
- P/E Ratio
- RNAC N/A
- CELC N/A
- Revenue Growth
- RNAC N/A
- CELC N/A
- 52 Week Low
- RNAC $11.67
- CELC $11.51
- 52 Week High
- RNAC $41.87
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- RNAC 40.64
- CELC 42.58
- Support Level
- RNAC $17.72
- CELC $11.94
- Resistance Level
- RNAC $26.50
- CELC $13.14
- Average True Range (ATR)
- RNAC 2.26
- CELC 0.51
- MACD
- RNAC -0.45
- CELC 0.07
- Stochastic Oscillator
- RNAC 0.00
- CELC 58.70
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.